Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study

64Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

Abstract

Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.

Cite

CITATION STYLE

APA

Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A., & Rommelaere, J. (2019). Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2019.01848

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free